Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710830 | 0.80 | GRM5 (0.67) | GRM5 | |
| SCHEMBL4712357 | 0.76 | GRM5 (0.62) | GRM5SLC6A2 | |
| SCHEMBL4713141 | 0.76 | GRM5 (0.54) | GRM5SLC6A2 | |
| SCHEMBL4711843 | 0.76 | GRM5 (0.54) | GRM5SLC6A2 | |
| SCHEMBL9302636 | 0.74 | CA12 (0.62) | GRM5SLC6A2 | |
| SCHEMBL31286312 | 0.74 | CA12 (0.62) | GRM5SLC6A2 | |
| SCHEMBL23707308 | 0.73 | GRM5 (0.36) | GRM5TRPV3 | |
| SCHEMBL7354283 | 0.73 | TRPV3 (0.39) | GRM5TRPV3 | |
| SCHEMBL17710274 | 0.72 | GRM5 (0.35) | GRM5TRPV3 | |
| SCHEMBL4710584 | 0.71 | GRM5 (0.52) | GRM5SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |